Vaccines for the common cold

The common cold is a spontaneously remitting infection of the upper respiratory tract, characterised by a runny nose, nasal congestion, sneezing, cough, malaise, sore throat, and fever (usually < 37.8 ºC). Whilst the common cold is generally not harmful, it is a cause of economic burden due to sc...

Full description

Saved in:
Bibliographic Details
Published in:Cochrane database of systematic reviews 2022-12, Vol.12 (12), p.CD002190
Main Authors: Montesinos-Guevara, Camila, Buitrago-Garcia, Diana, Felix, Maria L, Guerra, Claudia V, Hidalgo, Ricardo, Martinez-Zapata, Maria José, Simancas-Racines, Daniel
Format: Article
Language:English
Subjects:
Adenovirus Vaccines - adverse effects
Child
Child health
Common cold (coryza)
Common Cold - prevention & control
Ear, nose & throat
Humans
Incidence
Infectious disease
Lungs & airways
Male
Randomized Controlled Trials as Topic
Systematic Reviews as Topic
Vaccines, Attenuated - adverse effects
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The common cold is a spontaneously remitting infection of the upper respiratory tract, characterised by a runny nose, nasal congestion, sneezing, cough, malaise, sore throat, and fever (usually < 37.8 ºC). Whilst the common cold is generally not harmful, it is a cause of economic burden due to school and work absenteeism. In the United States, economic loss due to the common cold is estimated at more than USD 40 billion per year, including an estimate of 70 million workdays missed by employees, 189 million school days missed by children, and 126 million workdays missed by parents caring for children with a cold. Additionally, data from Europe show that the total cost per episode may be up to EUR 1102. There is also a large expenditure due to inappropriate antimicrobial prescription. Vaccine development for the common cold has been difficult due to antigenic variability of the common cold viruses; even bacteria can act as infective agents. Uncertainty remains regarding the efficacy and safety of interventions for preventing the common cold in healthy people, thus we performed an update of this Cochrane Review, which was first published in 2011 and updated in 2013 and 2017. To assess the clinical effectiveness and safety of vaccines for preventing the common cold in healthy people. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (April 2022), MEDLINE (1948 to April 2022), Embase (1974 to April 2022), CINAHL (1981 to April 2022), and LILACS (1982 to April 2022). We also searched three trials registers for ongoing studies, and four websites for additional trials (April 2022). We did not impose any language or date restrictions. Randomised controlled trials (RCTs) of any virus vaccine compared with placebo to prevent the common cold in healthy people. We used Cochrane's Screen4Me workflow to assess the initial search results. Four review authors independently performed title and abstract screening to identify potentially relevant studies. We retrieved the full-text articles for those studies deemed potentially relevant, and the review authors independently screened the full-text reports for inclusion in the review, recording reasons for exclusion of the excluded studies. Any disagreements were resolved by discussion or by consulting a third review author when needed. Two review authors independently collected data on a data extraction form, resolving any disagreements by consensus or by involving a third review author. We double-checked
ISSN:1469-493X
DOI:10.1002/14651858.CD002190.pub6